Kornimate/medical-research-clean huggingface dataset:
regional analgesia in combination with cryoanalgesia to prevent acute pain following nuss procedure

Conditions: Acute Pain; Regional Anesthesia

Summary: funnel chest deformation is a painful procedure, which requires high doses and long time used of opioids. it makes difficult introduction of eras protocol. intraoperative cryolesia of intercostal nerves serves great relief of pain after this procedures. however ablation of the nerves needs 12-24 hours to achieve effects. during this time the high doses of opioids are needed. it causes side effects (sedation makes rehabilitation difficult). on the other hand, percutaneus cryoablation performed 12-24 hours before nuss procedure needs repeated general anaesthesia. the investigators hypothesed that regional analgesia (erector spine plain block) performed just before intraopertive cryolesia may cover time to full cryolesia effect.

severe pain in the post-nuss procedure needs the use of many analgesic drugs, including opioids. it may cause adverse side effects and difficulties with rehabilitation. moreover, it increases the risk of complications and prolonged hospitalisation. cryoanalgesia as a part of multimodal analgesia offers better analgesia than single regional techiques with drugs and fasilitate introduction of the enhanced recovery after surgery (eras) protocol. however ablation of the nerves needs 12-24 hours to achieve effects. regional analgesia (erector spine plain block) performed just before intraopertive cryolesia may cover time to full cryolesia effect. this before - after study is a single institution pilot study designed to compare intraoperative cryolesia alone (control group) with the intervention group (cryolesia and bilateral erector spine plane block). it is designed for better management of acute pain in the pediatric population diagnosed with funnel-chest and treated using the modyfied nuss method. control group received standard care with cryolesia using the cryo-s painless device (metrum - cryoflex polska limited) and multimodal analgesia according the current guidelines. the intervention group received all of the above and regional analgesia (erector spine plain block, esp block). the aims of the study were the assessment the effectiveness of esp block before full action of intraoperative cryoanalgesia as a method of acute pain control, safety of the method. the results were compared in terms of demographics, pain levels, side effects of the pain relief medications in the postoperative period and lenght of hospitalization.

Eligibility criteria:
inclusion criteria: * patients undergoing pectus excavatum repair with modyfied minimal invasive thoracoscopic nuss technique * aged 10 years or above 10 up to 18 * informed consent signed for cryoanalgesia informed consent signed for regional analgesia exclusion criteria: * age of 9 years or below * refuse to receive cryoanalgesia or regional analgesia as primary pain relief * any contraindication to cryoanalgesia * difficult follow-up for geographical reasons and/or impossibility by the patient to understand how to perform self-measurements

Keywords: nuss procedure
quality control for chronic obstructive pulmonary disease

Conditions: COPD

Summary: this is a 1 year longitudinal study to establish a related index system for chronic obstructive pulmonary disease(copd) quality control.clinical and economic data of copd patients will be collected and analyzed.

sixteen hospitals in guangdong province were randomly divided into control group and intervention group.doctors and nurses of intervention group were trained treat chronic obstructive pulmonary disease according to the gold(global initiative of chronic obstructive lung disease) guidelines，while those in the control group will not receive any training from research team. hospital patient cohort and outpatient cohort will be setted. subjects were interviewed and received pulmonary function tests.all patients will be followed and events of acute exacerbation will be recorded.factors that influence patient prognosis and economic-health benefits will be analyzed.

Eligibility criteria:
inclusion criteria: * patients was diagnosed as copd according to global initiative for chronic obstructive lung disease (gold) guidelines older than 40 years old.patients was hospitalized for aecopd or visiting outpatient department for copd. * a signed and dated written informed consent is obtained prior to participation. * able to comply with the requirements of the protocol and be available for study visits over 1 years. exclusion criteria: a copd subject will not be eligible for inclusion in this study if any of the following criteria apply: * known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first ct scan), other than copd (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis) * having undergone lung surgery (e.g. lung reduction, lung transplant) * severe liver and kidney dysfunction * have cancer or have had cancer in the 5 years prior to study entry * taking part in a blinded drug study

Keywords: copd quality control
assessment of wrist joint and knee joint inflammation in patients with rheumatoid arthritis by quantitative three dimensional power doppler ultrasonography

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to: 1. to investigate the wrist joint synovial blood flow intensity and model by quantitative three-dimensional (3d) power doppler ultrasonography (pdus) in patients with rheumatoid arthritis before and after initiation of a new medicine and compare these data with routinely used clinical data and laboratory findings, such as pain score, erythrocyte sedimentation rate (esr) and c-reactive protein (crp) 2. to investigate the intra-observer and inter-observer agreement of quantitative 3d pdus assessment of the vascularity in wrist joints and knee joints using automatic volume scan.


Eligibility criteria:
inclusion criteria: * patients who fulfill the 1987 ara criteria for ra * patients with at least one painful swollen wrist or knee joint observed by a rheumatologist * patients who will receive a new medicine, including oral corticosteroid, intravenous methylprednisolone pulse therapy, intraarticular injection with steroid or methotrexate, dmards, or biologic agent exclusion criteria: * patients with active infection * patients with concurrent malignant disease * patients with a history of traumatic, septic, or cystal arthritis, previous joint surgery, or arthroscopic synovectomy of any wrist or kneejoint within the past 12 months before the study * patients who have severe wrist or knee joint deformity that makes the us assessment protocol unable to complete

Keywords: three-dimensional power doppler ultrasonography wrist knee rheumatoid arthritis
reducing mesh infections in open hernia repairs

Conditions: Patients Undergoing Open Hernia Repair; Patients Undergoing Ventral or Inguinal Hernia Repair

Summary: soaking meshes in a vancomycin solution just prior to their use in open hernia repairs will decrease rates of mesh infection


Eligibility criteria:
inclusion criteria: * open ventral or inguinal hernia repair exclusion criteria: * laparoscopic hernia repair * non ventral or inguinal hernia repairs
a study of degarelix in taiwanese patients with prostate cancer

Conditions: Prostate Cancer

Summary: a phase iii trial investigating the efficacy and safety of degarelix one-month depot in taiwanese patients with prostate cancer.


Eligibility criteria:
inclusion criteria: * 20 years or older * has a histological confirmed prostate cancer * has a screening serum testosterone above 1.5 ng/ml * has a eastern cooperative oncology group (ecog) score of ≤ 2 * has a screening psa value of ≥2 ng/ml * has a life expectancy of at least 168 days exclusion criteria: * current or previous hormone therapy * is currently treated with 5-α-reductase inhibitor * has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema * is considered to be a candidate for curative therapy, i.e radical prostatectomy or radiotherapy * has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin. * has a clinically significant disorder (other than prostate cancer) or any other condition , including alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the trial as judged by the investigator * has received an investigational drug within the last 28 days preceding screening visit or longer if considered to possibly influence the outcome of the current trial
effect of camel milk on insulin and incretin response

Conditions: Insulin Sensitivity; Glucose Tolerance

Summary: to examine the differential effect of camel and cow milk on the physiological response, to a liquid mixed-meal challenge, in people with normal glucose tolerance

camel milk is used as a traditional remedy throughout the middle east and indian subcontinent for conditions such as type 2 diabetes and dyslipidemia. it is currently unclear how such an effect could be mediated in vivo and studies are limited. we performed this study as a pilot experiment to assess the effects of camel milk on insulin, glucose, glp-1, c-peptide and lipid profile.

Eligibility criteria:
inclusion criteria: * normal glucose tolerance * bmi \< 30 kg/m2 exclusion criteria: * type 1 diabetes mellitus * type 2 diabetes mellitus * impaired fasting glucose or impaired glucose tolerance * lactose intolerance * weight loss / gain ≥ 5 kg in the preceding two months * use of estrogenic drugs or corticosteroids * known hypertriglyceridemia requiring treatment * history of heart attack, angina or cardiovascular disorder * history of malignant tumor * pregnant or lactating women * hemoglobin \< 12 for any reason * recent surgery or major hemorrhage * history of bariatric or metabolic surgery
gait modification for knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this randomized clinical trial will compare the changes in performance, biomechanical and clinical outcomes before and after a six-week gait modification intervention. participants with knee osteoarthritis will attend in-lab assessments and practice, while also performing daily, at-home walking tracked using a custom sensorized shoe.

greater toe-in or toe-out angles during walking are potential biomechanical management strategies for medial compartment knee osteoarthritis (oa). multi-week clinical trials demonstrate the biomechanical efficacy and potential clinical efficacy. however, walking biomechanics have only been assessed within laboratory environments and performance of the modifications during daily at-home walking is currently unknown. furthermore, the modifications have largely been instructed using a specific target, requiring motor learning. no study has examined whether a self-directed strategy is feasible and will produce significant improvements in biomechanical and clinical outcomes. moreover, objective real-world performance of these modifications is unknown and may explain the previous inconsistent clinical results. this study will address these gaps. the investigators hypothesize that real-world performance of the modifications will improve over the intervention and that both groups will exhibit improvements in biomechanical and clinical outcomes at follow up.

Eligibility criteria:
inclusion criteria: * be 50 years of age or greater * exhibit signs of tibiofemoral oa (a score of ≥ 2 on the kellgren and lawrence (kl) grading scale) predominantly in the medial compartment, * self-reported knee pain ≥ 3 / 10 on a numerical rating scale of pain (nrs; 0 = "no pain" and 10 = "worst pain imaginable") during most days of the previous month * are comfortable walking intermittently for 30 minutes * fit into the available sizes of sensorized shoes (sizes spanning us women's 5 to men's 13) * exhibit at least a 5% reduction in knee adduction moment impulse for 10 degrees of change to foot rotation measured during a screening appointment. exclusion criteria: * any knee surgery or intraarticular injections within the past 6 months * a history of joint replacement surgery or high tibial osteotomy * current or recent (within 6 weeks) corticosteroid injections * use of a gait aid * currently on a wait list for joint replacement surgery or high tibial osteotomy * any inflammatory arthritic condition * any other conditions that may affect normal gait or participation in an aerobic exercise program * cannot attend all required appointments.

Keywords: gait modification wearable sensors
evaluation of g-csf (colony stimulating factor) in patients with chronic chagas cardiomyopathy

Conditions: Chronic Chagasic Myocarditis

Summary: the purpose of this study is to evaluate the effectiveness of treatment with g-csf in patients with chronic heart failure secondary to chagas disease.


Eligibility criteria:
inclusion criteria: * diagnosis of chagas' disease confirmed by two serological tests with different methodologies; * diagnosis of chagas' cardiomyopathy in nyha functional classes ii, iii and iv of heart failure; * availability and willingness to participate, given the schedule of the study; * agreement and signing the written form. exclusion criteria: * acute systemic infections * solid neoplasms, myelodysplastic syndrome, acute or chronic myeloid leukemia, confirmed by imaging studies or past medical history; * valvulopathies with hemodynamic consequences; * autoimmune, pulmonary, or degenerative diseases, confirmed by imaging studies or past medical history; * severe renal, hepatic or thyroid dysfunction, confirmed by imaging studies or past medical history; * pregnancy (confirmed by examination of β hcg) or lactation; * known hypersensitivity to g-csf or to other components of the formula and / or hypersensitivity to proteins derived from e. coli.

Keywords: chagas disease g-csf cell therapy
lu af82422 in healthy non-japanese and japanese subjects and in patients with parkinson's disease

Conditions: Healthy; Parkinson Disease

Summary: the purpose of this study is to investigate the safety of a single dose of lu af82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-japanese and japanese subjects and in patients with parkinson's disease


Eligibility criteria:
inclusion criteria: healthy subjects: - men and women ≥18 and ≤55 years of age with a body mass index (bmi) ≥18 and ≤32 kg/m2 (non-japanese subjects) and ≥18 and ≤28 kg/m2 (japanese subjects) patients with parkinson's disease: * men and women with a clinical diagnosis of idiopathic parkinson's disease, hoehn and yahn (h\&y, stage 1-3) * for a minimum of three months prior to enrolment, parkinson's disease symptoms have been stable and is anticipated to be stable during the study duration as judged by the pi * if on parkinson's disease treatment the dose must be stable for a minimum of three months prior to enrolment and is anticipated to be stable during the study duration as judged by the pi * ≥40 and ≤80 years of age * bmi ≥18 and ≤35 kg/m2 exclusion criteria: * atypical parkinsonism * clinically relevant structural brain abnormality, as assessed using mri * mild cognitive impairment, measured as a montreal cognitive assessment (moca) score =\<21 * any past or current treatment with an active vaccine targeting alpha-synuclein * any past or current treatment with a monoclonal antibody within the last 12 months other in- and exclusion criteria may apply.
rapid detection of staphylococcus aureus in burn patients

Conditions: Burns; Sepsis

Summary: the purpose of this study is to determine if rapid early detection of the bacteria causing sepsis in burn patients improves patient outcomes.

burn patients have lost their primary barrier to microorganism invasion and therefore are continually and chronically exposed to pathogens. ninety-seven percent of patients with \>20% total body surface area (tbsa) burns develop septicemia; predominantly involving gram positive cocci including mrsa and methicillin sensitive staphylococcus aureus. blood culture (bc) is the traditional detection method for septicemia. however, antibiotics and inadequate sample volumes can impair detection by bc and results can take 3-4 days. polymerase chain reaction (pcr) represents a potential adjunct to bc. pathogens are detected in a growth-independent manner by targeting their genetic make-up. quantitative determining of pathogen dna using pcr could aid in determining antimicrobial drug therapy efficacy by providing results on the same testing day as opposed to 3-4 days with bc. pcr may also detect persistent infections during antimicrobial therapy when culture samples are inhibited. the aims of this study are:(1)to correlate quantitative pcr results with that of the bc; (2) to test the clinical application of pcr results with clinical outcomes of treatment of presumptive diagnosis of staphylococcal sepsis.

Eligibility criteria:
inclusion criteria: * 20% or \> tbsa burns at hospital admission * will require bc during hospital stay * patient/surrogate able to sign consent exclusion criteria: * allergic to nafcillin, cefazolin, vancomycin, linezolid, and/or daptomycin * on antibiotic(s) prior to first bc

Keywords: burn sepsis infection
study of bronchiectasis and associated cardiovascular comorbidities

Conditions: Bronchiectasis

Summary: effect of cardiovascular comorbidities on disease severity and quality of life in patients with acute exacerbation of non-cystic fibrosis bronchiectasis

the study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using sf-36 quality of life questionnaire. we will also study the inflammatory markers in both groups using d-dimer, bnp, and crp and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.

Eligibility criteria:
inclusion criteria: • any patients with bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period. exclusion criteria: * any patients who refuse to participate in the study. * any other comorbidity or end-organ failure may affect the study's result.
effects of nicotine in tobacco smokers

Conditions: Smoking, Tobacco; Smoking (Tobacco) Addiction

Summary: this study will examine mechanisms linking obsessive-compulsive disorder symptomatology to tobacco dependence.


Eligibility criteria:
inclusion criteria: * at least 21 years old * daily smoking at least 2 years exclusion criteria: * currently pregnant or breastfeeding.

Keywords: smoking
tumor registry pancreatic cancer

Conditions: Pancreas Cancer

Summary: the registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in germany. the registry will follow up patients for two years. it will identify common sequences of treatments used as well as changes in the treatment of the disease. health-related quality of life will be analysed during the course of the treatment (panlife). based on the available data a prognostic score will be developed.


Eligibility criteria:
inclusion criteria: * resectable or locally advanced/metastatic pancreatic cancer * 18 years and older * antineoplastic treatment * date of consent no later than 2 weeks after start of first-line treatment exclusion criteria: * no pancreatic cancer * below 18 years and older * no antineoplastic treatment * date of consent later than 2 weeks after start of first-line treatment

Keywords: pancreatic neoplasms neoplasms registry advanced pancreatic cancer health services research epidemiology germany palliative treatment palliative care localized, resectable pancreatic cancer adjuvant treatment
the effects of facilitated percutaeous coronary intervention in acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study to investigate whether the administration of high-dose tirofiban before primary pci could reduce myocardial infarct size, using analysis of contrast-enhanced magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset * st-segment elevation more than 1 mm in two or more contiguous leads or presumably a new-onset left bundle branch blockage exclusion criteria: * hemodynamic instability * history of mi * old age \> 80years * patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, gastrointestinal or genitourinary bleeding within the prior 3 months)

Keywords: angioplasty, transluminal, percutaneous coronary tirofiban magnetic resonance imaging myocardial infarction
efficacy and safety of ly01011 and xgeva® in patients with bone metastases from solid tumors

Conditions: Bone Metastases From Solid Tumors

Summary: this is a multicenter，randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of ly01011 (recombinant anti-rankl human monoclonal antibody injection) and xgeva® in patients with bone metastases from solid tumors.

the primary objective is to evaluate the similarity of clinical efficacy between ly01011 and xgeva® in patients with bone metastases from solid tumors. the secondary objective is to evaluate the similarity of clinical safety and immunogenicity between ly01011 and xgeva® in patients with bone metastases from solid tumors. each subject will participate in the study for 53 weeks. treatments are administered on day 1 and q4w thereafter through week 49. all patients are instructed to take 500 mg calcium and 400 iu vitamin d daily.

Eligibility criteria:
inclusion criteria: * the subject or his/her guardian and/or impartial witness voluntarily signed the written informed consent form（icf）. * aged 18 to 80 years old (female or male subjects to the date of signing the informed consent form). * subjects with solid tumor confirmed by histological or cytological examination. at least one documented bone metastasis confirmed by computed tomography\[ct\], magnetic resonance imaging\[mri\]) or pathology (bone biopsy). * eastern cooperative oncology group（ecog）performance status≤2. * adequate organ function at baseline. exclusion criteria: * prior treatment with denosumab or other rankl-targeted therapeutic drugs. * subjects who previously received any bone-modifying agents (including intravenous or oral bisphosphonates, etc.) for advanced tumor disease. * orthopedic surgery or bone-related radiation therapy within 1 month prior to first dose. bone radioisotope therapy within 6 months prior to first dose, or planned radiation therapy or surgery for bone during the study. * past or ongoing osteomyelitis or osteonecrosis of the jaws （onj）, an active dental or jaw condition requiring oral surgery, non-healed dental or oral surgery, or any planned invasive dental procedure during the study period. * primary central nervous system malignancy. subjects with central nervous system metastases who have failed local therapy. subjects with asymptomatic brain metastases or clinically stable brain metastases who do not require steroids and other therapy for brain metastases for ≥ 28 days may be enrolled.